News


All series


All News

A new agent aimed at treating symptomatic vitreomacular adhesion can affect patients differently depending on several components.

A better understanding of how genetic risk factors influence the trajectory of age-related macular degeneration may be key to solving the puzzles of this disease. Ocular tissue research may play a role in that process.

Ultra-widefield fluorescein angiography may help improve treatment in patients with recalcitrant diabetic macular edema by visualizing areas of peripheral nonperfusion that can benefit from targeted photocoagulation.

Lasers continue to have a place in the treatment of diabetic macular edema with foveal involvement despite the advent of anti-VEGF therapy.

The therapeutic pipeline for neovascular age-related macular degeneration (AMD) contains a host of promising investigational agents. Only time will tell how any one will shape the future of AMD management.

Though the scenic backdrop of the Pacific Northwest at this year’s meeting of the Association for Research in Vision and Ophthalmology (ARVO) may have been different from the traditional Floridian seascape, the meeting’s world-class science continues to be at the forefront.

United Kingdom’s National Institute for Health and Care Excellence (NICE) has provisionally recommended ocriplasmin (Jetrea, ThromboGenics NV) for reimbursement within the National Health Service (NHS).

The Cole Eye Institute will present a Retina Summit CME symposium immediately before the ARVO 2013 annual meeting.